The Peter Attia Drive cover image

#75 - David Light: Zantac recall due to cancer concerns – what you need to know

The Peter Attia Drive

00:00

Ranitidine Under Fire: Safety Concerns and Testing Failures

This chapter examines the role of the FDA in drug safety, focusing on ranitidine and Zantac's cancer risk controversies. It highlights alarming levels of NDMA found in these medications, surpassing FDA limits, and emphasizes the need for more rigorous independent testing. The discussion reveals significant implications for patient safety and calls for new approaches to pharmaceutical oversight.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app